Glyclada

Glyclada is a prescription oral medication that contains the active ingredient gliclazide, a second‑generation sulfonylurea, formulated for the treatment of type 2 diabetes mellitus. It is marketed in the European Union and is taken by mouth. The product’s strength and dosage form are not specified in the available data, and it is supplied only with a physician’s prescription.

Glyclada is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents are insufficient.

- Improves glycemic control by stimulating insulin release from pancreatic β‑cells. - Used as monotherapy in patients newly diagnosed with type 2 diabetes. - Can be combined with metformin or other oral antidiabetic agents when additional glucose lowering is needed. - May be prescribed when other sulfonylureas are not tolerated. - Intended for chronic use as part of a comprehensive diabetes management plan.

The safety profile of Glyclada reflects the typical effects observed with sulfonylurea agents, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Low blood sugar (hypoglycemia) - Nausea or abdominal discomfort - Headache - Dizziness

Serious: - Severe allergic reaction such as skin rash or swelling - Persistent hypoglycemia leading to loss of consciousness

Before starting Glyclada, healthcare providers assess several clinical factors to minimize risks and ensure appropriate use.

- Verify diagnosis of type 2 diabetes and assess renal and hepatic function. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use in patients with known sulfonylurea hypersensitivity. - Monitor blood glucose regularly, especially during dose adjustments. - Counsel patients on recognizing and managing hypoglycemia symptoms.

Glyclada may interact with other medicines, affecting its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which can cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide plasma levels. - MAO‑B inhibitors, which can potentiate hypoglycemic effects.

Use with caution: - Co‑administration with beta‑blockers may mask hypoglycemia symptoms. - Combination with thiazide diuretics may require closer glucose monitoring.